Monoclonal Antibody Therapy
Anti-COVID-19 Monoclonal Antibodies Information
- Monoclonal antibody therapy has been shown to reduce the risk of developing COVID-19 after an exposure, and to reduce the risk of hospitalization or death in high-risk individuals who are infected.
- Can be given either as an injection or infusion
- Not FDA approved, but rather has an Emergency Use Authorization for adults and children between ages 12-17 weighing over 40 kg (88 lb)
Who qualifies for Anti-COVID-19 Monoclonal Antibodies?
The FDA defines who qualifies for Anti-COVID-19 Monoclonal Antibodies, and guidance is specific whether infected or exposed.
If infected with COVID-19
- Individuals must have symptoms of COVID-19, be within 10 days of symptom onset and have a high-risk condition*. Persons hospitalized for COVID-19 or on supplemental oxygen are not candidates for monoclonal antibody therapy.
If exposed to COVID-19
- Individuals must be within 7 days of exposure, have insufficient immunity to COVID (i.e. are unimmunized, incompletely immunized, or fully vaccinated but immunocompromised) and have a high-risk condition*.
- Older than 65 years
- Obesity or overweight
- Chronic kidney disease
- Immunosuppressive disease or immunosuppressive treatment
- Cardiovascular disease or high blood pressure
- Chronic lung disease
- Sickle cell disease
- Neurodevelopmental disorders
- Tracheostomy, gastrostomy, or positive pressure ventilation (not for COVID)
What to Expect
- Call your Virginia Mason health care provider to discuss next steps if you believe you qualify for anti-COVID-19 monoclonal antibody treatment.
- Your care team will guide you through steps to determine your eligibility, provide pre-treatment counseling, and arrange for treatment.
- You will receive the medication either as an intravenous infusion or as 4 injections.
- The FDA requires that you be observed for 1 hour after you have received the medication.
- For additional information, please review the FDA patient fact sheet.